China Sky One Medical signs distribution agreement with Shaanxi

Naftopidil dispersible tablets are used to treat benign enlargement of the prostate in middle-aged men.

Peng Lai Jin Chuang Pharmaceutical will monitor and appraise Shaanxi Buchang Group’s sales performance annually and maintains the right to terminate the distribution agreement if Shaanxi Buchang does not meet its expected sales target.

Yan-Qing Liu, chairman and CEO of China Sky One Medical, said: “We look forward to a successful collaboration with Shaanxi Buchang on the sale of naftopidil dispersible tablets. As part of our growth strategy, we will continue to seek out favorable collaborative agreements in R&D, production and sales to further grow the business.”